July 2nd, 2009

Podcast 48: A conversation with Les Irwig, which your bone scanner won’t like to hear.

(1 votes, average: 2.00 out of 5)

Scanning patients on bisphosphonates within the first 3 years of therapy is just wasted effort, and may even be misleading clinically. That’s what researchers conclude after reanalysis of FIT trial data on some 6500 women taking either alendronate or placebo. Prof. Les Irwig of the University of Sydney talks about his team’s findings and what they mean for clinicians used to doing densitometric studies to reassure patients about the progress of their therapy.

This week’s news links:

This week’s Interview links:

Comments are closed.

Clinical Conversations

About the Podcast

To subscribe: Subscribe on iTunes

To have your comment included in a future podcast, call 617-440-4374. Please leave your name, number, and the podcast ID number.